Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo, SmithKline merge - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 13, 2000

    Glaxo, SmithKline merge

    With the Federal Trade Commission (USA) finally, approving the Glaxo–SmithKline merger, the merger between Indian affiliates is also on the anvil. Infact, changes in the management structure in Glaxo have been happening over the last three months to put in place a structure for the unified entity.

    First, came the appointment of Mr. Thiyagrajan who took over from Mr. Khusrokhan as CEO of the company. Mr. Thiyagrajan, headed Glaxo operations in the South East Asia and his coming back to head Glaxo’s operations were seen as the parent’s desire to merge the operations of the two companies sooner than later. Next came the replacements of Mr. Bandopadhaya, VP, Information Technology and Mr. Anil Mathai, VP, Exports by SmithKline officials.

    There have also been press reports that two divisions of Glaxo – the veterinary division Agrivet Farm Care and Qualigens Fine Chemicals are on the block. The management however, has denied these reports.

    There is also the question of what happens to sister concerns of these two companies viz. Burroughs Wellcome and SmithKline Consumer. There is also another entity, SmithKline Beecham Asia, a 100% subsidiary of the SmithKline. (Glaxo, does not have a presence in India via a 100% subsidiary.) This however, is likely to serve as the 100% arm of the merged entity.

    Burroughs was not merged into Glaxo in India because of the fact, that wages for the workers in Burroughs were higher than those in Glaxo. While the management was willing to make a one time payment, the workers were adamant. This prompted the management to keep the company separate, though the marketing operations of Burroughs were integrated with Glaxo.

    SmithKline Consumer owns the ‘Horlicks’ brand and is the market leader in the malted food segment. It recently took over ‘Maltova’ and ‘Viva’ too. However, internationally, SmithKline is more of a pharma company with the major operations of ‘Horlicks’ concentrated in the UK, apart from a sizeable presence in India. Glaxo has already sold its foods portfolio (comprising ‘Farex’ and ‘Glucon D’) worldwide. Even in India the food division was sold to Heinz.

    We have tried to hypothecate about the merger ratio between the two companies assuming of course that Burroughs Wellcome and SmithKline Consumer are kept out of the merger temporarily. If one were to make a forecast the full year earnings, Glaxo would end up reporting a net in the range of Rs 820 m, SmithKline would in all probability end up with a net in the range of of Rs 240 m.

    Assuming a 1:2.5 ratio (i.e. 2.5 shares of SmithKline for every 1 share of Glaxo), the merged entity would end up with an equity of around Rs 716 m (post merger) and a per share earnings of Rs.14.80.

    At a price earnings of around 35, the merged company could quote at levels of Rs 520–530. While Glaxo currently quotes at a price of Rs 479, SmithKline Pharma is quoting at the price of 208. The current market prices are actually indicative of a 1:2.3 ratio (i.e. one share of Glaxo for every 2.3 shares of SmithKline Pharma).



    Equitymaster requests your view! Post a comment on "Glaxo, SmithKline merge ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts